A Registered Cohort Study on Spastic Paraplegia
ConditionSpastic Paraplegia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorWan-Jin Chen
About this trial
The aim of this study is to determine the clinical spectrum and natural progression of Hereditary Spastic Paraplegias(HSP) and related disorders in a prospective multicenter natural history study, to assess the clinical, genetic and epigenetic features of patients with Spastic Paraplegias to optimize clinicalmanagement..
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with the clinical diagnosis of spastic paraplegia
Clinical diagnosis of patients with spastic paraplegia
Unrelated healthy controls
Disqualifiers
Decline to participate.
There are serious interferences with individual participation and adherence to the research protocol, including but not limited to neurological, psychological, and/or medical conditions.
Trial population
Patients diagnosed in hosipital and their's family
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
- Other intervention
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Spastic Paraplegia Rating Scale (SPRS)
Disease severity will be assessed by application of the Spastic Paraplegia Rating Scale (SPRS), a clinical rating scale measuring disease severity in Hereditary Spastic Paraplegia (Schule et al. Neurology 2006). The SPRS contains 13 items, each ranging from 0 to 4 points. The total score is calculated as the sum of all items, yielding a range for the total score between 0 and 52. Hereby, higher SPRS total scores indicate more severe disease.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Wan-Jin Chen
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Sponsor institution
Source ClinicalTrials.gov